Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients

Inclusion Criteria: patients should meet all of the following criteria * Ambulatory patients age ≥ 18 years * Written informed consent prior to admission to the trial. * No diabetes as confirmed by HbA1c \<6.5%, fasting serum glucose \<126 mg/dL, and review of concomitant medications and medical history * Diagnosis of Heart failure (NYHA II to III) * LVEF \> 50% * On medical therapy for heart failure consistent with prevailing cardiovascular guidelines at a stable dose for ≥4 weeks prior to screening, except for diuretics which must have been stable for ≥2 weeks prior to screening * Women of child-bearing potential must agree to use birth control measures with a failure rate of \<1% per year during the treatment period of the study Exclusion Criteria: * Type 1 and Type 2 diabetes * Acute coronary syndrome (ACS) or cardiac surgery within the last week. * Pregnant or lactating women, * Acute decompensated HF or hospitalized for HF within 1 month from screening visit * Glomerular Filtration Rate (GFR) \< 25 ml/ min/1.73m2, * Patients on drugs with potential interaction with sotagliflozin including digoxin, phenytoin, HIV medication and rifampin. * Receiving SGLT2-I 3-months prior to randomization. * non-MRI compatible PM or ICD and any other medical or physical condition considered unappropriated by a study physician.